Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65% in Trial
Summary: Merck and Kelun-Biotech announced Phase 3 clinical trial results...
Sources on this story
Reported by 1 sources, including:
- STAT News
More AI-scored stories
- Israel's Volatile Election Season Begins with Integrity Warnings and Coalition Chaos
- Death toll in Venezuela earthquakes rises to 5,398
- US escalates strikes on Iran with B-1 bomber in first since resumption of conflict
- Unicredit reports best half-year in history with €6.3 billion profit
- Rheinmetall Expands Gunpowder Production to Address European Ammunition Shortage
- India and ASEAN Discuss Action Plan for 2026-2030 Cooperation
- Trump returns to Georgia with election claims, worrying some Republicans
- US Education Department probes five medical schools over admissions practices